Market Overview

Benzinga's Top Downgrades

Benzinga's Top Downgrades
Related CPHD
Proxy Statement Shows Danaher Faced Competition In Bid To Buy Cepheid
Benzinga's Top Downgrades
Related ABT
Amid Headline Risk, Barclays Says St. Jude's Pipeline Underestimated
Fed Speakers And Beige Book, Bank Earnings, Rising Crude Take Center Stage
SetPoint Leads The Crohn's Medtech Race By Being The Only Entrant (Seeking Alpha)

Analysts at Piper Jaffray downgraded Cepheid (NASDAQ: CPHD) from “overweight” to “neutral.” Cepheid's shares closed at $34.09 yesterday. Cepheid's trailing-twelve-month ROE is -12.52%.

Analysts at Deutsche Bank downgraded Abbott Laboratories (NYSE: ABT) from “buy” to “hold.” Abbott's shares closed at $33.27 yesterday. Abbott's PEG ratio is 0.51.

Analysts at Goldman Sachs downgraded Wells Fargo & Company (NYSE: WFC) from “buy” to “neutral.” Wells Fargo's shares closed at $34.76 yesterday. Wells Fargo's trailing-twelve-month profit margin is 23.18%.

Raymond James downgraded First Solar (NASDAQ: FSLR) from “market perform” to “underperform.” First Solar's shares closed at $34.41 yesterday. First Solar's trailing-twelve-month ROA is 2.17%.

Latest Ratings for CPHD

Sep 2016BairdDowngradesOutperformNeutral
Sep 2016CitigroupDowngradesBuyNeutral
Sep 2016BairdMaintainsOutperform

View More Analyst Ratings for CPHD
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings


Related Articles (CPHD + ABT)

View Comments and Join the Discussion!